Biogen BIIB will report second-quarter 2025 results on July 31, before market open. In the last reported quarter, the company's earnings missed expectation by 7.4%. The Zacks Consensus Estimate for ...

EMA committee recommends marketing approval for Biogen’s Zurzuvae to treat women with postpartum depression: Cambridge, Massachusetts Monday, July 28, 2025, 17:00 Hrs [IST] Biog ...

Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

Two weeks after Supernus unveiled the Sage Therapeutics acquisition, all 338 employees from the struggling biotech are being laid off.

Biogen (NASDAQ:BIIB), and Ionis Pharmaceuticals (NASDAQ:IONS) announced that the European Medicines Agency (EMA) has given positive endorsements for their products. The EMA's Committee for Medicinal ...

Some women’s symptoms improved quickly after taking the pill, but depression persisted in others. Doctors are trying to learn ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products for Human Use (CHMP) has ...

More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real ...

Calling Supernus’ offer for Sage fair, the RBC analysts noted that Biogen may still come in with a higher bid. Barron’s reached out to both Biogen and Sage for comment.

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Biogen, with a price target of $224.00. The company’s shares closed yesterday at $130.13. Do ...

Detailed price information for Atai Life Sciences N.V. (ATAI-Q) from The Globe and Mail including charting and trades.

Sage Therapeutics is laying off most of its employees after announcing its planned acquisition earlier this month.